United States v. Hackensack Med Ctr , 495 F.3d 103 ( 2007 )


Menu:
  •                                                                                                                            Opinions of the United
    2007 Decisions                                                                                                             States Court of Appeals
    for the Third Circuit
    7-17-2007
    USA v. Hackensack Med Ctr
    Precedential or Non-Precedential: Precedential
    Docket No. 06-2287
    Follow this and additional works at: http://digitalcommons.law.villanova.edu/thirdcircuit_2007
    Recommended Citation
    "USA v. Hackensack Med Ctr" (2007). 2007 Decisions. Paper 659.
    http://digitalcommons.law.villanova.edu/thirdcircuit_2007/659
    This decision is brought to you for free and open access by the Opinions of the United States Court of Appeals for the Third Circuit at Villanova
    University School of Law Digital Repository. It has been accepted for inclusion in 2007 Decisions by an authorized administrator of Villanova
    University School of Law Digital Repository. For more information, please contact Benjamin.Carlson@law.villanova.edu.
    PRECEDENTIAL
    UNITED STATES COURT OF APPEALS
    FOR THE THIRD CIRCUIT
    No. 06-2287
    UNITED STATES OF AMERICA, EX REL;
    PHIL HEFNER, UNITED STATES OF AMERICA, EX REL.
    v.
    HACKENSACK UNIVERSITY MEDICAL CENTER;
    CENTER FOR INFECTIOUS DISEASES, P.A.;
    NORTH JERSEY PRIMARY CARE ASSOCIATES, P.A.
    Phil Hefner,
    Appellant
    On Appeal from the United States District Court
    for the District of New Jersey
    (D.C. Civil No. 01-cv-04078)
    District Judge: Hon. Dennis M. Cavanaugh
    Argued June 4, 2007
    BEFORE: SMITH and COWEN,
    and SILER*, Circuit Judges
    (Filed July 17, 2007)
    *Honorable Eugene E. Siler, Jr., Senior United States Circuit
    Judge, U.S. Court of Appeals for the Sixth Circuit, sitting by
    designation.
    Victor A. Kubli, Esq. (Argued)
    Grayson & Kubli
    1420 Sprint Hill Road, Suite 230
    McLean, VA 22102
    Counsel for Appellant
    Stuart A. Minkowitz, Esq.
    Office of the United States Attorney
    970 Broad Street, Rm. 700
    Newark, NJ 07102
    Michael E. Robinson, Esq.
    United States Department of Justice
    Civil Division, Appellate Staff
    601 D. Street, N.W.
    Washington, DC 20530
    Eric J. Feigin, Esq. (Argued)
    United States Department of Justice
    Civil Division
    950 Pennsylvania Avenue, N.W.
    Washington, DC 20530
    Counsel for Appellee United States of
    America, ex rel.
    John Z. Jackson, Esq. (Argued)
    Kalison, McBride, Jackson & Murphy
    25 Independence Boulevard, 4 th Floor
    Warren, NJ 07059
    Counsel for Appellee Hackensack Medical
    Center
    2
    Joseph M. Gorrell, Esq. (Argued)
    Brach, Eichler, Rosenberg, Silver,
    Bernstein, Hammer, Gladstone
    101 Eisenhower Parkway
    Roseland, NJ 07068
    Counsel for Appellee Center for Infectious
    Diseases, P.A.
    John H. Schmidt, Jr., Esq. (Argued)
    Lindabury, McCormick, Estabrook
    & Cooper
    53 Cardinal Drive
    P.O. Box 2369
    Westfield, NJ 07091
    Counsel for Appellee North Jersey Primary
    Care Associates, P.A.
    OPINION
    COWEN, Circuit Judge.
    Phil Hefner appeals from an order entered by the United
    States District Court for the District of New Jersey, denying
    reconsideration of its order granting summary judgment in favor
    of defendant-appellees, and denying an alternate remedy
    pursuant to 
    31 U.S.C. § 3730
    (c)(5). For the reasons stated
    below, we will affirm.
    I.
    Hackensack University Medical Center (“HUMC”)
    operates a medical university and hospital. The North Jersey
    Primary Care Associates, P.A. (“NJPC”), a professional service
    corporation that is effectively controlled by HUMC, manages
    HUMC’s physician staffing. HUMC provides treatment to
    patients with infectious diseases at the Infectious Diseases Clinic
    3
    (the “Clinic” or the “HUMC Clinic”), among other clinics.
    Dr. Steven Sperber, a board-certified infectious disease
    physician, treated patients at the HUMC Clinic. He did so in his
    individual capacity through an agreement with NJPC, not as a
    member of the Center for Infectious Diseases (“CID”), which is
    a private practice of infectious disease physicians, including
    Sperber. Incidentally, the CID and HUMC are separate entities,
    although CID leased some medical office space from, and used
    the support services of, HUMC.
    The services which Dr. Sperber provided at the HUMC
    Clinic were covered under a grant, specifically, the National
    Institute of Health Ryan White Title I Grant (“the Grant”), which
    provided federal funding for the treatment of AIDS patients.
    Maryann Collins, the AIDS Coordinator for HUMC, applied for
    and administered the Grant on behalf of HUMC.
    To administer the Grant, Collins submitted to the
    government monthly invoices itemizing the allowable services
    and requesting reimbursement. In support of the invoices,
    Collins signed certifications that included the following:
    I certify that none of the above service units have
    been previously submitted and paid; all of the
    billable units are in compliance with the authorized
    budget and contracted for scope of service.
    Additionally, all services below have been provided
    and/or delivered as specified.
    One of the conditions of the Grant was that it could not be
    used to replace existing financial support. Thus, the Grant
    provided “[f]unds may not be used to provide items or services
    for which payment has already been made or can reasonably be
    expected to be made by a third-party payer, including . . .
    Medicare.” HUMC understood this provision to mean that it
    was entitled to reimbursement by the Grant for services that
    were payable by Medicare, as long as it did not bill Medicare.
    This was an incorrect interpretation, as confirmed by a study
    conducted by the Grant’s administrator, the Health Resources
    4
    and Services Administration (“HRSA”), which determined that
    Medicare should be the payer of first resort. The HRSA study
    also found, however, that 85% of hospitals surveyed had billing
    problems arising from third-party payer/grant situations.
    Nevertheless, HUMC failed to conform to even its
    incorrect interpretation of its responsibilities under the Grant.
    While Collins included fees for Dr. Sperber’s services in grant
    invoices, HUMC also charged Medicare for the same services.
    This was caused by a breakdown in HUMC’s billing system.
    According to Thomas Flynn, HUMC’s Director of Compliance,
    billing information was generated by physicians and then sent to
    the physician billing department. There, billing staff clerks
    entered claims into the system. Flynn explained that for claims
    that were reimbursable by the Grant, the clerk was supposed to
    enter an allowance code that would indicate as much. However,
    because there had been some staff turnover, the staff member
    who was responsible for entering the allowance code was not
    doing so. This left a receivable in the system, which caused bills
    to go out to Medicare.
    In June 2000, Marilyn Capek, an administrator at CID,
    received a form from NJPC asking Dr. Sperber to reassign his
    payments from Medicare to NJPC. Capek thought that Dr.
    Sperber’s services at HUMC were being paid for by the Grant,
    so she called Collins to ask about the discrepancy. Collins
    promised to investigate and then passed along this information to
    Flynn. Flynn instructed the physician billing staff to run a report
    to determine if any claims connected to Dr. Sperber’s work had
    been submitted to Medicare. When the report disclosed that
    claims had been submitted to Medicare, such billing was
    stopped, and Flynn began reviewing the records to determine
    how many claims had been submitted in error so that HUMC
    could repay Medicare.
    Around this time, HUMC engaged the services of Health
    Systems Management Network (“HSMN”), a consulting firm, to
    help improve its compliance with documentation and billing
    regulations. Relator Hefner was hired by HSMN on June 20,
    2000, and was assigned to HUMC on July 5, 2000. The next
    5
    day, Hefner had a meeting with Theodore Tarantini, the senior
    managing partner of HSMN, and Mark Clachko, a member and
    chairman-elect of the HUMC Medical Board. Hefner arrived at
    the meeting two hours late, looking disheveled, and provided a
    “totally outrageous” excuse for his tardiness. Tarantini
    concluded that Hefner was an alcoholic, a big problem for
    HSMN, and was not up to doing his job. Soon after this
    meeting, Hefner had a second meeting with Tarantini, and again
    arrived looking disheveled.
    Clachko was also unhappy with Hefner’s performance.
    After a July 11, 2000 meeting with Hefner, Clachko told the co-
    chairman of performance improvement and quality assurance at
    HUMC that he was “extremely, extremely upset” with Hefner,
    and that Hefner “was inappropriate, acted very strange, and did
    not offer any advice or suggestions on any corporate compliant
    [sic] issues.” Clachko was apparently so upset with Hefner that
    he was ranting and raving. After this conversation, HUMC
    called HSMN and asked that Hefner be replaced.
    After Hefner and Clachko’s meeting, Hefner met with
    Capek. During this meeting, Capek told Hefner that she had
    come across some paperwork that suggested there might be a
    problem with double billing concerning the Grant. Capek also
    stated, however, that she had brought it to HUMC’s attention
    and the company was working on remedying the problem.
    During her deposition, Capek referred to the act of double billing
    as a “fraud.” She stated, “Well, you can’t bill Medicare and
    receive federal grants at the same time, that’s fraud.”
    Immediately after this meeting, HUMC ordered Hefner
    off HUMC premises. Hefner was officially terminated by
    HSMN six days later.
    In September 2000, HUMC informed Medicare that
    services reimbursed under the Grant had been wrongly charged
    to Medicare. HUMC then returned the payments–totaling
    $5258.97–to Medicare.
    II.
    6
    Hefner filed a qui tam action under seal in the United
    States District Court for the District of Maryland against HUMC.
    Thereafter, the United States filed a Notice of Election to
    Decline Intervention, and the complaint was unsealed. The
    matter was transferred to the District of New Jersey, and Hefner
    filed an amended complaint that added NJPC and CID as
    defendants.
    Hefner’s amended complaint contained three claims
    under the False Claims Act (“FCA”), 
    31 U.S.C. §§ 3729-33
    : (1)
    submitting false claims and false invoices; (2) making false
    records and false statements; and (3) retaliatory discharge. After
    discovery, the District Court granted summary judgment to all
    defendants on all counts. Hefner moved for partial
    reconsideration. Hefner also requested that, if the District Court
    denied his motion for reconsideration, he receive a share of
    HUMC’s repayment to the government as an alternate remedy to
    his FCA action. The District Court denied Hefner’s motion for
    reconsideration and denied his request for a share of the
    administrative repayment. Hefner now appeals.
    III.
    We have jurisdiction over this appeal by virtue of 
    28 U.S.C. § 1291
    . The District Court’s order granting appellees’
    motions for summary judgment is subject to plenary review.
    Carter v. McGrady, 
    292 F.3d 152
    , 157 (3d Cir. 2002).1 We
    review the District Court’s order denying reconsideration of its
    1
    Although Hefner did not specify the order granting
    summary judgment in his notice of appeal, we will exercise
    jurisdiction over the unspecified order because there is a definite
    connection between the order denying the motion for
    reconsideration of the order granting summary judgment and the
    summary judgment order itself. See Williams v. Guzzardi, 
    875 F.2d 46
    , 49 (3d Cir. 1989). Moreover, appellees have not been
    prejudiced by Hefner’s failure to specify the summary judgment
    order in the notice of appeal since they have fully briefed the issue
    of whether the grant of summary judgment was appropriate.
    7
    order granting summary judgment for an abuse of discretion.
    Harsco Corp. v. Zlotnicki, 
    779 F.2d 906
    , 909 (3d Cir. 1985).
    Finally, we engage in a de novo review of the District Court’s
    order denying an alternate remedy pursuant to 
    31 U.S.C. § 3730
    (c)(5), because the issue turns on a question of law.
    Shuman ex rel. Shertzer v. Penn Manor Sch. Dist., 
    422 F.3d 141
    ,
    146 (3d Cir. 2005).
    IV.
    Hefner presents four arguments on appeal. First, he
    argues that the District Court should not have granted summary
    judgment to HUMC and NJPC on his first and second FCA
    claims because he presented evidence that their conduct satisfied
    the FCA’s scienter requirement. Second, he argues that the
    District Court should not have granted summary judgment to
    CID on his FCA claims because CID operated as an integrated
    enterprise with HUMC and NJPC. Third, he argues that he
    presented sufficient evidence to withstand summary judgment on
    his retaliatory discharge claim. Finally, he argues that the
    District Court erred in ruling that he was not entitled to a share of
    HUMC’s repayment to the government. We consider each
    argument in turn below.
    A.
    Hefner argues that the District Court erred in granting
    summary judgment to HUMC and NJPC on his FCA claims. He
    posits that when HUMC submitted bills to both the Grant and
    Medicare, it violated the statute. For the reasons stated below,
    we agree with the District Court that Hefner did not present
    sufficient evidence for a reasonable jury to conclude that
    appellees’ conduct satisfied the FCA’s scienter requirement.
    To establish a prima facie case under the FCA, the relator
    must prove: “(1) the defendant presented or caused to be
    presented to an agent of the United States a claim for payment;
    (2) the claim was false or fraudulent; and (3) the defendant knew
    the claim was false or fraudulent.” Hutchins v. Wilentz,
    Goldman & Spitzer, 
    253 F.3d 176
    , 182 (3d Cir. 2001). Here, it is
    8
    undisputed that Hefner established the first and second prongs.
    However, the District Court ruled that Hefner failed to present
    sufficient evidence for a reasonable jury to conclude that
    appellees knew the claims were false or fraudulent, which is the
    only issue now in dispute.
    The False Claims Act defines “knowing” as including a
    defendant’s “actual knowledge,” “deliberate ignorance,” or
    “reckless disregard” of the truth or falsity of information in the
    defendant’s claim to the government. 
    31 U.S.C. § 3729
    (b).
    Further, “no proof of specific intent to defraud is required.” 
    Id.
    Congress specifically expressed “‘its intention that the act not
    punish honest mistakes or incorrect claims submitted through
    mere negligence.’” United States ex rel. Hochman v. Nackman,
    
    145 F.3d 1069
    , 1073 (9th Cir. 1998) (quoting S. Rep. No.
    99-345, at 7 (1986)).
    Hefner has presented no evidence that appellees had
    actual knowledge that the claims they submitted were false. He
    argues that his case is analogous to United States ex rel. Cantekin
    v. University of Pittsburgh, 
    192 F.3d 402
     (3d Cir. 1999), where
    we did find evidence of actual knowledge of falsity. In
    Cantekin, the relator submitted an affidavit stating that he had
    told the defendant that he should disclose his industry
    funding–which was the subject of the FCA claim–to the
    government. 
    Id. at 411
    . According to the affidavit, the
    defendant rejected this suggestion, stated that his other grants
    were none of the government’s business, and then continued to
    omit reference to the industry funding. 
    Id.
     This certainly
    presents evidence that the defendant knew the disclosure forms
    he submitted to the government were false: he was approached
    with evidence that he was submitting false claims, expressed no
    interest in correcting the falsehood, and continued to submit the
    false statements.
    Here, on the other hand, Hefner has not presented any
    evidence showing that the individuals submitting the claims to
    the government knew that they were submitting false claims.
    Although Hefner claims that the appellees’ knowledge is
    established by virtue of Capek’s statements to him indicating that
    9
    HUMC was double billing and engaging in “fraud,” 2 Capek was
    not the one submitting the claims; she was the one who happened
    to catch the error. And when she realized what had happened,
    she informed HUMC staff, who rectified the problem. Capek’s
    after-the-fact interpretation of the situation does not establish that
    the individuals submitting the claims knew that they were
    submitting false claims. Indeed, in Capek’s deposition
    testimony, she explained how she perceived the situation: “I felt
    that something had slipped through the cracks, they weren’t
    aware of it.” Hefner has presented no evidence of actual
    knowledge except this insufficient statement of Capek’s, and
    accordingly, the District Court was correct to reject this
    argument.
    Moreover, Hefner has failed to present sufficient evidence
    for a reasonable jury to conclude that appellees’ billing errors
    were made in reckless disregard of their truth. He argues that
    because Collins “didn’t do anything” to ensure that the
    certifications she submitted to the Grant were correct, she was
    reckless. However, Collins explained that she did not do
    anything because she “work[ed] in a system whereby different
    parts of the system are in place to assure [compliance], and to the
    best of my knowledge, they were in place, and what I wrote
    down and what I signed off to was what I believe[d] to be true.”
    Hefner has presented no evidence that Collins had reason to
    believe that the billing system employed by HUMC was not up to
    the task of separating Medicare and non-Medicare bills, and
    accordingly, her failure to call the billing department about every
    claim to ensure that it had not been billed elsewhere was not
    reckless.
    Hefner also argues that appellees were reckless because
    2
    Even if Capek did describe the conduct as fraud, her
    deposition testimony demonstrates that her use of the word “fraud”
    does not say anything about her evaluation of the person’s state of
    mind, which is the only issue here. When discussing the double
    billing, she stated “Well, you can’t bill Medicare and receive
    federal grants at the same time, that’s fraud.”
    10
    they did not have a compliance system in place. However, this
    distorts the record. In 1998, HUMC created a compliance
    department, with Flynn as director. Part of the compliance
    department’s responsibility was to manage and audit medical
    records, coding, and billing–which includes Medicare claims.
    This department formalized practices that were already in place.
    Although it is true that the compliance department was not
    concerned with invoices sent to the Grant, it was actually on the
    Medicare side–which the department did monitor–where the
    system broke down. The mere failure of a system to catch an
    error does not establish recklessness. See Wang v. FMC Corp.,
    
    975 F.2d 1412
    , 1420-21 (9th Cir. 1992) (poor job performance
    and innocent mistakes are not actionable under the False Claims
    Act).
    HUMC’s lack of recklessness is also demonstrated, at
    least indirectly, by its hiring HSMN to help it improve its
    compliance. Furthermore, there is no evidence that the
    government had any idea about the double billing, and thus
    HUMC’s repayment to the government appears entirely
    voluntary. As the Seventh Circuit has explained, “[j]udging by
    the apparently satisfactory conclusion in the eyes of the Medical
    Center and the government’s refusal to take up this action, it
    appears that no party to the incident believes any harm was
    done.” Hindo v. Univ. of Health Sciences/The Chi. Med. Sch., 
    65 F.3d 608
    , 614 (7th Cir. 1995).
    Accordingly, we agree with the District Court’s
    conclusion that Hefner presented insufficient evidence for a
    reasonable jury to find liability against HUMC and NJPC under
    the FCA. Moreover, because we conclude that HUMC and
    NJPC were not liable, a fortiori, CID cannot be held liable under
    an integrated enterprise or agency theory. Hence, we will affirm
    the grant of summary judgment to all appellees on the first and
    second FCA claims and affirm the denial of the motion for
    reconsideration.
    B.
    Hefner next argues that he was terminated from his
    11
    position at HSMN in retaliation for his investigation of HUMC’s
    fraud, in violation of 
    31 U.S.C. § 3730
    (h). In order to establish a
    claim under § 3730(h), Hefner must show “(1) he engaged in
    protected conduct, (i.e., acts done in furtherance of an action
    under § 3730) and (2) that he was discriminated against because
    of his protected conduct.” Hutchins, 
    253 F.3d at 186
     (internal
    quotation marks omitted). For a plaintiff to demonstrate that he
    was discriminated “against ‘because of’ conduct in furtherance
    of a False Claims Act suit, a plaintiff must show that (1) his
    employer had knowledge he was engaged in ‘protected conduct’;
    and (2) that his employer’s retaliation was motivated, at least in
    part, by the employee’s engaging in ‘protected conduct.’” 
    Id.
    Hefner alleges that he was engaging in protected conduct
    when he learned about billing irregularities from Capek. Even if
    we accept this statement, there is no evidence in the record that
    Hefner’s employer–whether construed as HSMN or
    HUMC–knew that he was acting in furtherance of an FCA claim
    when it fired him. All the evidence in the record shows that
    Hefner was removed from the HUMC building almost
    immediately after he met with Capek and before he talked to
    anyone from HUMC about what he had learned. The record is
    entirely bereft of evidence that Hefner’s employer knew that he
    was engaged in protected conduct. The District Court was thus
    correct to grant summary judgment against Hefner on this claim.
    C.
    Hefner’s final argument is that the District Court was
    wrong to reject his claim to a share of the money repaid by
    HUMC to the government. Under the FCA, the United States
    may “elect to pursue its claim through any alternate remedy
    available to the Government, including any administrative
    proceeding to determine a civil money penalty.” 
    31 U.S.C. § 3730
    (c)(5). If the government does pursue an alternate remedy,
    however, “the person initiating the action shall have the same
    rights in such proceeding as such person would have had if the
    action had continued under this section.” 
    Id.
     Hefner argues that
    when the government accepted the repayment from HUMC, it
    pursued an alternate remedy under § 3730(c)(5), and he is
    12
    therefore entitled to a share of the proceeds. The government
    argues, on the other hand, that it would be perverse to permit
    Hefner any recovery because his underlying FCA suit is
    meritless.3
    This Court has not considered the issue of whether a
    relator has a legal right to recover a share of the proceeds of an
    alternate remedy when his qui tam action is invalid. In United
    States ex rel. Merena v. SmithKline Beecham Corp., 
    205 F.3d 97
    ,
    106 (3d Cir. 2000), we addressed a related issue: whether a qui
    tam relator whose claim is subject to dismissal for being based
    on publicly disclosed information is entitled to a share of
    settlement proceeds attributable to that claim. We ultimately
    concluded that such a relator is not entitled to a share of the
    government’s proceeds, but our analysis was based upon a close
    “examin[ation] [of] both section 3730(e)(4) and section
    3730(d).” 
    Id. at 103
    . Since this case does not implicate §
    3730(e)(4), we do not view Merena as controlling authority for
    the government’s position in this case. But taking our cue from
    Merena, we will engage in a close examination of the applicable
    statutory provisions in determining whether a relator, whose qui
    tam claims are proven invalid, is entitled to any share of the
    proceeds of an alternate remedy attributable to those claims.
    In analyzing the issue before us, we are aided by the
    opinions of two of our sister courts. In United States ex rel.
    Bledsoe v. Community Health Systems, Inc., 
    342 F.3d 634
    , 650
    (6th Cir. 2003), the Court of Appeals for the Sixth Circuit opined
    that “a threshold requirement for a relator’s ability to share in the
    proceeds of a FCA lawsuit is to file a valid qui tam action.”
    There, the government argued that because the relator had failed
    to comply with Rule 9(b)’s heightened pleading requirement, he
    was not entitled to share in the government’s settlement with the
    3
    The government alternatively argues that it never pursued
    an “alternate remedy” within the meaning of 
    31 U.S.C. § 3730
    (c)(5). Because we conclude that Hefner does not have a right
    to share in the repayment because his qui tam claim lacked merit,
    we need not reach the government’s alternative argument.
    13
    defendant health care provider. 
    Id.
     Citing to § 3730(b)(1),
    which permits the relator to bring “a civil action for a violation
    of section 3720,” the court agreed that a valid qui tam action is a
    “threshold requirement” for a relator’s eligibility to share in an
    alternate remedy. Id. Ultimately, however, the court decided to
    remand the case to give the relator an opportunity to replead,
    thereby allowing the case to proceed. Id.
    Like the Sixth Circuit, the Court of Appeals for the Ninth
    Circuit has recognized that a valid qui tam action is a prerequisite
    to a relator’s right to recover. See Donald v. University of
    California Board of Regents, 
    329 F.3d 1040
     (9th Cir. 2003). In
    Donald, the relators filed a qui tam suit against the Regents of
    the University of California, in which the government intervened
    and then negotiated a settlement. The government subsequently
    broke off negotiations with the relators, reasoning that under
    recent Supreme Court precedent, “a private party may not bring a
    qui tam action against a state entity under § 3729(a) of the FCA.”
    Id. at 1044. The court agreed that the relators had no statutory
    right to a recovery under the FCA because “[a] private party . . .
    has a legal right to recovery only from a qui tam action brought
    pursuant to § 3730(b)(1), which is in turn dependent on the
    private party having a valid cause of action under § 3729(a).” Id.
    Thus, the invalidity of the qui tam action foreclosed the relators’
    claim to a share of the government’s proceeds from its
    settlement. Id.; see also id. at 1044 n.5 (“[A] relator has a right
    to recover a share of the proceeds of the alternate remedy to the
    same degree that he or she would have been entitled to a share of
    the proceeds of an FCA action.” (internal quotation marks
    omitted)).
    Like our sister courts, we read the relevant statutory
    provisions to mean that a relator is not entitled to a share in the
    proceeds of an alternate remedy when the relator’s qui tam action
    under § 3729 is invalid: As § 3730(c)(5) provides, a relator’s
    rights in an alternate remedy proceeding are the “same rights”
    that the relator would have had if the action had proceeded under
    the FCA. The relator’s rights to a qui tam award in an FCA
    action are delineated in § 3730(d), which section applies only in
    “an action brought by a person under subsection (b).” Id. §
    14
    3730(d)(1). Subsection (b), in turn, refers to an action brought
    for “a violation of section 3729.” Id. § 3730(b)(1). The statute
    evinces no intent to compensate relators who bring unfounded §
    3729 claims, whether the claims are legally or factually
    unfounded.
    Because Hefner’s qui tam action is invalid for failing to
    present evidence that the false claims were knowingly submitted,
    he is not entitled to a share of the government’s repayment.
    Accordingly, we find no error in the District Court’s order
    denying him a share of the alleged alternate remedy.
    For the foregoing reasons, the judgment of the District
    Court entered on March 27, 2006 will be AFFIRMED.
    15